Literature DB >> 14659659

Modification of mitogen-driven lymphoproliferation by ceftriaxone in normal and immunocompromised mice.

Maria Jimenez-Valera1, Encarnacion Moreno, Maria Angeles Amat, Alfonso Ruiz-Bravo.   

Abstract

Cyclophosphamide-treated mice are proposed as a model to assay immunomodulation by antimicrobial agents in immunocompromised animals. Cyclophosphamide-treated BALB/c mice developed temporary leukopenia, myelopenia and spleen atrophy that was followed by splenomegaly. Cells from both atrophic and hypertrophic spleens exhibited impaired responses to mitogens and suppressed the mitogen-driven proliferation of normal splenocytes. This experimental model was applied to the study of immunomodulation by ceftriaxone. Ceftriaxone did not worsen the cyclophosphamide-damaged immunity mechanisms. On the contrary, cyclophosphamide-induced suppression of lymphoproliferation in response to concanavalin A was attenuated by ceftriaxone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14659659     DOI: 10.1016/j.ijantimicag.2003.04.001

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  3 in total

1.  In vitro lymphoproliferative response and cytokine production in mice with experimental disseminated candidiasis.

Authors:  Ali Reza Khosravi; Hojjatollah Shokri; Shahin Eshghi
Journal:  Iran J Basic Med Sci       Date:  2017-02       Impact factor: 2.699

2.  Monitoring Cellular Immune Responses after Consumption of Selected Probiotics in Immunocompromised Mice.

Authors:  Seok-Jin Kang; Jun Yang; Na-Young Lee; Chang-Hee Lee; In-Byung Park; Si-Won Park; Hyeon Jeong Lee; Hae-Won Park; Hyun Sun Yun; Taehoon Chun
Journal:  Food Sci Anim Resour       Date:  2022-09-01

Review 3.  Immunomodulatory activity of Lactobacillus plantarum KLDS1.0318 in cyclophosphamide-treated mice.

Authors:  Yueyue Meng; Bailiang Li; Da Jin; Meng Zhan; Jingjing Lu; Guicheng Huo
Journal:  Food Nutr Res       Date:  2018-03-21       Impact factor: 3.894

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.